Inflamed Language: FDA Sends Harsh Warning Letter To Allergan For Acne Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
Allergan gets slammed for Aczone Gel promotional claims that FDA says are backed by data "not even nominally statistically significant."
You may also be interested in...
FDA And Allergan Resume Promotional Battle After Settling First Amendment Suit
DDMAC letter objects to direct mail piece implying Lumigan is superior to Xalatan in lowering intraocular pressure. FDA had cited Allergan for similar claims in 2005.
FDA And Allergan Resume Promotional Battle After Settling First Amendment Suit
DDMAC letter objects to direct mail piece implying Lumigan is superior to Xalatan in lowering intraocular pressure. FDA had cited Allergan for similar claims in 2005.
DDMAC Gets Aggressive On Downplaying Risk Info, Sends Three Letters In Three Weeks
Materials aimed at patients and professionals targeted in letters to Iroko, Eisai and Shire.